Daylight-PDT: Everything Under the Sun

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2022 Apr 6

PMID 35385082

Authors

Dana Beiki

Ian M Eggleston

Charareh Pourzand

Affiliations

Soon will be listed here.

Abstract

5-Aminolevulinic acid-based photodynamic therapy (ALA-PDT) was first implemented over three decades ago and has since been mainly part of clinical practice for the management of pre-cancerous and cancerous skin lesions. Photodynamic therapy relies on the combination of a photosensitizer, light and oxygen to cause photo-oxidative damage of cellular components. 5-Aminolevulinic acid (ALA) is a natural precursor of the heme biosynthetic pathway, which when exogenously administered leads to the accumulation of the photoactivatable protoporphyrin IX. Although, effective and providing excellent cosmetic outcomes, its use has been restricted by the burning, stinging, and prickling sensation associated with treatment, as well as cutaneous adverse reactions that may be induced. Despite intense research in the realm of drug delivery, pain moderation, and light delivery, a novel protocol design using sunlight has led to some of the best results in terms of treatment response and patient satisfaction. Daylight PDT is the protocol of choice for the management of treatment of multiple or confluent actinic keratoses (AK) skin lesions. This review aims to revisit the photophysical, physicochemical and biological characteristics of ALA-PDT, and the underlying mechanisms resulting in daylight PDT efficiency and limitations.

Citing Articles

Reactive Oxygen Species-Sensitive Nanophotosensitizers Composed of Buthionine Sulfoximine-Conjugated Chitosan Oligosaccharide for Enhanced Photodynamic Treatment of Cancer Cells.

Lee H, Park J, Kim T, Kim T, Kim D, Yun J Int J Mol Sci. 2024; 25(23).

PMID: 39684320 PMC: 11641636. DOI: 10.3390/ijms252312609.

Advances in Medicine: Photodynamic Therapy.

Aebisher D, Szpara J, Bartusik-Aebisher D Int J Mol Sci. 2024; 25(15).

PMID: 39125828 PMC: 11311490. DOI: 10.3390/ijms25158258.

The use of photodynamic therapy in medical practice.

Aebisher D, Rogoz K, Mysliwiec A, Dynarowicz K, Wiench R, Cieslar G Front Oncol. 2024; 14:1373263.

PMID: 38803535 PMC: 11129581. DOI: 10.3389/fonc.2024.1373263.

Application of fluorocarbon nanoparticles of I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer.

Zhi L, Cheng C, Jing L, Zhi-Ping P, Lu Y, Yan T J Nanobiotechnology. 2024; 22(1):107.

PMID: 38475902 PMC: 10929118. DOI: 10.1186/s12951-024-02309-7.

Topical 5-aminolevulinic acid (ALA)-photodynamic therapy (PDT) for lichen sclerosus of face: case report and literature review.

Tommasino N, Lauletta G, Spano G, Scaramuzzino L, De Fata Salvatores G, Scalvenzi M Lasers Med Sci. 2024; 39(1):53.

PMID: 38291288 DOI: 10.1007/s10103-024-04004-3.

References

Philipp-Dormston W, Karrer S, Petering H, Ulrich C, Dirschka T, Berking C . Daylight PDT with MAL - current data and practical recommendations of an expert panel. J Dtsch Dermatol Ges. 2015; 13(12):1240-9. DOI: 10.1111/ddg.12807. View

Reelfs O, Abbate V, Hider R, Pourzand C . A Powerful Mitochondria-Targeted Iron Chelator Affords High Photoprotection against Solar Ultraviolet A Radiation. J Invest Dermatol. 2016; 136(8):1692-1700. PMC: 4946793. DOI: 10.1016/j.jid.2016.03.041. View

Kasche A, Luderschmidt S, Ring J, Hein R . Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol. 2006; 5(4):353-6. View

Correia J, Rodrigues J, Pimenta S, Dong T, Yang Z . Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions. Pharmaceutics. 2021; 13(9). PMC: 8470722. DOI: 10.3390/pharmaceutics13091332. View

Gunaydin G, Gedik M, Ayan S . Photodynamic Therapy-Current Limitations and Novel Approaches. Front Chem. 2021; 9:691697. PMC: 8223074. DOI: 10.3389/fchem.2021.691697. View

Jomaa A, Gamerdinger M, Hsieh H, Wallisch A, Chandrasekaran V, Ulusoy Z . Mechanism of signal sequence handover from NAC to SRP on ribosomes during ER-protein targeting. Science. 2022; 375(6583):839-844. PMC: 7612438. DOI: 10.1126/science.abl6459. View

Lacour J, Ulrich C, Gilaberte Y, Von Felbert V, Basset-Seguin N, Dreno B . Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol. 2015; 29(12):2342-8. DOI: 10.1111/jdv.13228. View

Ash C, Dubec M, Donne K, Bashford T . Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. Lasers Med Sci. 2017; 32(8):1909-1918. PMC: 5653719. DOI: 10.1007/s10103-017-2317-4. View

Wong T, Morton C, Collier N, Haylett A, Ibbotson S, McKenna K . British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018. Br J Dermatol. 2018; 180(4):730-739. DOI: 10.1111/bjd.17309. View

10.

Juzenas P, Juzeniene A, Kaalhus O, Iani V, Moan J . Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo. Photochem Photobiol Sci. 2003; 1(10):745-8. DOI: 10.1039/b203459j. View

11.

van den Akker J, Holroyd J, Vernon D, Sterenborg H, Brown S . Comparative in vitro percutaneous penetration of 5-aminolevulinic acid and two of its esters through excised hairless mouse skin. Lasers Surg Med. 2003; 33(3):173-81. DOI: 10.1002/lsm.10212. View

12.

Cantisani C, Paolino G, Bottoni U, Calvieri S . Daylight-Photodynamic Therapy for the Treatment of Actinic Keratosis in Different Seasons. J Drugs Dermatol. 2015; 14(11):1349-53. View

13.

Robinson D, de Bruijn H, de Wolf W, Sterenborg H, Star W . Topical 5-aminolevulinic acid-photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluorescence kinetics, photobleaching and biological effect. Photochem Photobiol. 2001; 72(6):794-802. DOI: 10.1562/0031-8655(2000)072<0794:TAAPTO>2.0.CO;2. View

14.

Inoue K, Karashima T, Kamada M, Shuin T, Kurabayashi A, Furihata M . Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas. Pathobiology. 2009; 76(6):303-14. DOI: 10.1159/000245896. View

15.

Lesar A, Ferguson J, Moseley H . A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin. Photodermatol Photoimmunol Photomed. 2009; 25(4):191-5. DOI: 10.1111/j.1600-0781.2009.00436.x. View

16.

Apalla Z, Sotiriou E, Panagiotidou D, Lefaki I, Goussi C, Ioannides D . The impact of different fluence rates on pain and clinical outcome in patients with actinic keratoses treated with photodynamic therapy. Photodermatol Photoimmunol Photomed. 2011; 27(4):181-5. DOI: 10.1111/j.1600-0781.2011.00595.x. View

17.

LaRochelle E, Marra K, LeBlanc R, Shane Chapman M, Maytin E, Pogue B . Modeling PpIX effective light fluence at depths into the skin for PDT dose comparison. Photodiagnosis Photodyn Ther. 2019; 25:425-435. DOI: 10.1016/j.pdpdt.2019.01.022. View

18.

Buchczyk D, Klotz L, Lang K, Fritsch C, Sies H . High efficiency of 5-aminolevulinate-photodynamic treatment using UVA irradiation. Carcinogenesis. 2001; 22(6):879-83. DOI: 10.1093/carcin/22.6.879. View

19.

Ibbotson S, Stones R, Bowling J, Campbell S, Kownacki S, Sivaramakrishnan M . A consensus on the use of daylight photodynamic therapy in the UK. J Dermatolog Treat. 2016; 28(4):360-367. DOI: 10.1080/09546634.2016.1240863. View

20.

van der Veen N, de Bruijn H, Berg R, Star W . Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice. Br J Cancer. 1996; 73(7):925-30. PMC: 2074259. DOI: 10.1038/bjc.1996.165. View